Lightnews — Scholar-powered news

Joel Topf @kidneyboy.bsky.social · 4h

That feels like a feature that open evidence will add soon enough

Reposted by Joel Topf

David M. Perry @lollardfish.bsky.social · 6h

- My talk is too long
- But maybe if I read it fast
- Lots of people have tried this
- It didn't work for those people
- But maybe ...

16 12 220

Joel Topf @kidneyboy.bsky.social · 5h

Try open evidence.
www.openevidence.com

Then tell me, who the hell is paying $580 for UpToDate

2 5

Reposted by Joel Topf

wormbuxx @wormbuxx.bsky.social · 1d

Now I’m falling asleep and she’s calling a cob

44 670 3.7K

Joel Topf @kidneyboy.bsky.social · 1d

Which fucker at the ABIM thought that the day that IM board scores came out was a good day to do scheduled maintenance?

7

Reposted by Joel Topf

Nephrology Journal Club @nephjc.bsky.social · 2d

1/10
Welcome to #TenPostNephJC
Last #NephJC we discussed tolerance induction in HLA matched 🫘 transplants with donor Hematopoietic stem cells (MDR-101).
Missed the Chimeri-chat? No worries - We’re quite “tolerant” to those who missed their IS(Informative Session)!

pubmed.ncbi.nlm.nih.gov/39922283/

1 6 7

Joel Topf @kidneyboy.bsky.social · 2d

From Richard Lafayette at GlomCon

2 2 4

Joel Topf @kidneyboy.bsky.social · 2d

but mandating treatment with something that is not available as SoC is also a little crazy.

And "allowing" is an escape hatch from the ethical dilemma of enrolling a patient on sub state-of-the-art therapy for the length of the trial (thankfully, only a year at this time)

1 1 1

Joel Topf @kidneyboy.bsky.social · 2d

And allow use of SGLT2i and sparsentan or atrasentan as long as they are started before study drug is initiated

No conventional steroids
No coated budesonide

1

Joel Topf @kidneyboy.bsky.social · 2d

makes for an interesting question, why should countries where the drugs will not be available enroll patients in trials?

The control group I am seeing in new IgAN trials:
requiured ACEi or ARB at maximum tolerated doses but no titration period like in Fidelio/Figaro trials

2 1 2

Reposted by Joel Topf

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 3d

Want to get your own version of #NephJC merch such as this pretty and useful backpack? 🎒

Donate to a good cause and get some swag too

www.nephjc.com/news/2025/9/...

1 4 8

Reposted by Joel Topf

clyde bruckman's ghost's final repost says free link @ultralaser.bsky.social · 4d

terrible things are happening outside. poor helpless people are being dragged out of their homes. families are torn apart. men, women, and children are separated. children come home from school to find that their parents have disappeared.

diary of anne frank, january 13, 1943.

18 1.5K 2.9K

Joel Topf @kidneyboy.bsky.social · 4d

I think we are having a raging agreement. I'm all in favor of active controls. In fact at our research center we are refusing to consider any trials with drug against ACEi/ARB/Flozin. That ship has sailed.

1 1 4

Joel Topf @kidneyboy.bsky.social · 4d

Dan Dickerson is legendary. He is no sacrifice.

1

Joel Topf @kidneyboy.bsky.social · 4d

According to my sources FS1

1 1

Reposted by Joel Topf

Tom Nichols @radiofreetom.bsky.social · 4d

“People who care about music don’t charge for concert tickets”
“People why care about art and drama don’t charge for plays and movies”

Steve.bannon.stan @steve-bannon-stan.bsky.social · 4d

I agree. People who care about being read don’t ask people to pay.

24 17 180

Joel Topf @kidneyboy.bsky.social · 4d

Okay this is a very cool gadget. Love the amplification of Eko. Don't love that it auto corrects to Elon (that little fuck is everywhere)

9

Reposted by Joel Topf

Jonathan Pollack @jonathanpollack.bsky.social · 5d

Fascinating that CLYM116 is compared to sibe in a preclinical study. Hope we see more head-to-head comparisons with other leading or emerging agents!

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN | Climb Bio

New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with init...

ir.climbbio.com

1 3 5

Joel Topf @kidneyboy.bsky.social · 4d

Not just hard to recruit, but with KDIGO guidelines pushing aggressive therapy down to less sick patients (only 0.5g proteinuria) it will be unethical

1 1 7

Reposted by Joel Topf

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 9d

Very strange post singling out Voclosporin and lupus nephritis from the FDA CDER chap

www.linkedin.com/posts/george... since deleted already

h/t @ericweinhandl.bsky.social and @grahamabra.bsky.social

1 3 7

Reposted by Joel Topf

Conor Sen @conorsen.bsky.social · 4d

Really good update — there aren’t even any negotiations going on right now. And neither Thune nor Johnson feels empowered to cut a deal. It’s basically a staring contest.

Sahil Kapur @sahilkapur.bsky.social · 4d

Weirdest government shutdown ever

12 30 120

Reposted by Joel Topf

International Society of Glomerular Disease @isgd.bsky.social · 5d

PARASOL Project is expanding focus to include biomarkers & endpoints in APOL1 kidney disease and primary MN as well as FSGS. Learn more: eu1.hubs.ly/H0nr8Lv0
@tobias-b-huber.bsky.social @miktmc.bsky.social @jarcyzphd.bsky.social @ohiostatemed.bsky.social @utoronto.ca @nu-nephrology.bsky.social

PARASOL Project Expands Focus to APOL1, Membranous Nephropathy

PARASOL Project expands to focus on APOL1 kidney disease and primary membranous nephropathy, aiming to improve clinical trial endpoints for these conditions.

eu1.hubs.ly

4 6

Joel Topf @kidneyboy.bsky.social · 6d

Fasting for Yom Kippur doesn't hit quite as hard in the GLP1ra era #Atonement

1 1 7

Reposted by Joel Topf

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · Nov 14

Ok you guys asked for it!

IMO it’s a banal story of misguided moderators

Or petty people who want to wield their power

You decide

1/

1 2 3

Reposted by Joel Topf

Stephen P Juraschek, MD, PhD, FAHA, AHSCP-CHS @spjuraschek.bsky.social · 7d

Enough is enough:

RETREAT-FRAIL www.nejm.org/doi/full/10....

OPTIMISE
www.thelancet.com/journals/lan...

DANTON
academic.oup.com/ageing/artic...

No mortality benefit (and potentially harm) from antihypertensive deprescription among frail older adults. Meta-analyze that!

Reduction of Antihypertensive Treatment in Nursing Home Residents | NEJM

Among older adults with frailty, evidence on the benefits and risks of discontinuing antihypertensive drugs is limited. In a multicenter, randomized, controlled trial conducted in France, we assign...

www.nejm.org

1 7 19